Evidence map›Paper›PMID 33646600›Full record

ArticleAdvanced healthcare materials2021

Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model.

Hamilton Kakwere, Hua Zhang, Elizabeth S Ingham, Marina Nura-Raie, Spencer K Tumbale, Riley Allen, Sarah M Tam, Bo Wu, Cheng Liu, Azadeh Kheirolomoom and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Shifting cold to hot tumors by nanoparticle-loaded drugs and products.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Article
  6. New Strategies for Macrophage Re-Education in Cancer: An Update.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hamilton KakwereMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.ORCID 0000-0002-1934-4992
Hua ZhangMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Elizabeth S InghamDepartment of Biomedical Engineering, University of California (Davis), Davis, CA, 95616, USA.
Marina Nura-RaieMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Spencer K TumbaleMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Riley AllenDepartment of Biomedical Engineering, University of California (Davis), Davis, CA, 95616, USA.
Sarah M TamDepartment of Biomedical Engineering, University of California (Davis), Davis, CA, 95616, USA.
Bo WuMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Cheng LiuMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Azadeh KheirolomoomMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Brett Z FiteMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Asaf IlovitshMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Jamal S LewisDepartment of Biomedical Engineering, University of California (Davis), Davis, CA, 95616, USA.
Katherine W FerraraMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA.
Stanford Medicine · USUniversity of California, Davis · US

Funding

Specific and high-resolution ultrasound cancer imagingR01CA112356 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI FERRARA, KATHERINE W, FOIRET, JOSQUIN · 2005 to 2022
$6.1M
Imaging Modulation of Immune PhenotypeR01CA250557 · NCI · STANFORD UNIVERSITY · PI FERRARA, KATHERINE W, LEVY, RONALD · 2021 to 2025
$3.2M
Image-guided ultrasound therapy and drug delivery in pancreatic cancerR01CA210553 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2016 to 2020
$3.2M
HIFU-immunotherapy in pancreatic cancerR01CA253316 · NCI · STANFORD UNIVERSITY · PI FERRARA, KATHERINE W · 2020 to 2024
$3.1M
NCI NIH HHS R01 CA112356NCI NIH HHS R01 CA210553NCI NIH HHS R01 CA250557NCI NIH HHS R01 CA253316
6 · The paper itself

Abstract

Resiquimod is an immunopotent toll-like receptor 7/8 agonist with antitumor activity. Despite being potent against skin cancers, it is poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparation of degradable nanoparticles with covalently bound resiquimod and their systemic application in cancer immunotherapy is reported. Dispersion in water of amphiphilic constructs integrating resiquimod covalently bound via degradable amide or ester linkages yields immune-activating nanoparticles. The degradable agonist-nanoparticle bonds allow the release of resiquimod from the carrier nanoparticles. In vitro assays with antigen presenting cells demonstrate that the nanoparticles retain the immunostimulatory activity of resiquimod. Systemic administration of the nanoparticles and checkpoint blockade (aPD-1) to a breast cancer mouse model with multiple established tumors triggers antitumor activity evidenced by suppressed tumor growth and enhanced CD8

Indexed as

Breast NeoplasmsNanoparticlesAnimalsCD8-Positive T-LymphocytesHumansImidazolesImmunityImmunotherapyMiceMicellesPolymersImidazolesMicellesPolymersresiquimodimmunotherapymetastatic breast cancernanotechnologyresiquimodtoll-like receptor agonistvaccines

Identifiers

PMID33646600
PMCPMC8153207
OpenAlexW3134595554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.